The average one-year price target for Ionis Pharmaceuticals (NasdaqGS:IONS) has been revised to $85.25 / share. This is an increase of 10.27% from the prior estimate of $77.31 dated November 7, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $46.46 to a high of $115.50 / share. The average price target represents an increase of 19.15% from the latest reported closing price of $71.55 / share.
What is the Fund Sentiment?
There are 765 funds or institutions reporting positions in Ionis Pharmaceuticals. This is an increase of 70 owner(s) or 10.07% in the last quarter. Average portfolio weight of all funds dedicated to IONS is 0.23%, an increase of 17.71%. Total shares owned by institutions decreased in the last three months by 1.32% to 193,158K shares. 
The put/call ratio of IONS is 0.56, indicating a bullish outlook.
What are Other Shareholders Doing?
T. Rowe Price Investment Management holds 13,157K shares representing 8.12% ownership of the company. In its prior filing, the firm reported owning 16,049K shares , representing a decrease of 21.98%. The firm increased its portfolio allocation in IONS by 31.41% over the last quarter.
Capital World Investors holds 12,723K shares representing 7.85% ownership of the company. In its prior filing, the firm reported owning 12,540K shares , representing an increase of 1.43%. The firm increased its portfolio allocation in IONS by 57.87% over the last quarter.
FDGRX - Fidelity Growth Company Fund holds 7,671K shares representing 4.74% ownership of the company. In its prior filing, the firm reported owning 7,595K shares , representing an increase of 0.98%. The firm increased its portfolio allocation in IONS by 3.07% over the last quarter.
Wellington Management Group Llp holds 6,589K shares representing 4.07% ownership of the company. In its prior filing, the firm reported owning 6,346K shares , representing an increase of 3.69%. The firm decreased its portfolio allocation in IONS by 76.54% over the last quarter.
Bellevue Group holds 6,244K shares representing 3.86% ownership of the company. In its prior filing, the firm reported owning 7,853K shares , representing a decrease of 25.76%. The firm increased its portfolio allocation in IONS by 2.73% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
